
 
													 
									 
															 
															Year
 
															DEALS // DEV.
 
															Country
 
															 
															Therapeutic Area
 
															Study Phase
 
															Deal Type
 
															Product Type
 
															Dosage Form
 
															Lead Product
 
															Target

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : YL201
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Akeso
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study of YL201 and Ivonescimab (AK112) in Advanced Solid Tumors
Details : YL201 is a Antibody-drug Conjugate drug candidate, which is currently being evaluated in Phase I/ Phase II clinical studies for the treatment of Neoplasms.
Product Name : Undisclosed
Product Type : Antibody-drug Conjugate
Upfront Cash : Inapplicable
October 06, 2025
Lead Product(s) : YL201
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Akeso
Deal Size : Inapplicable
Deal Type : Inapplicable

A Study of YL202 in Patients With Advanced Solid Tumors
Details : YL202 is a Antibody-drug Conjugate drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Carcinoma, Non-Small-Cell Lung.
Product Name : Undisclosed
Product Type : Antibody-drug Conjugate
Upfront Cash : Inapplicable
October 01, 2025

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : YL242
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study of YL242 in Subjects With Advanced Solid Tumors
Details : YL242 is a Antibody-drug Conjugate drug candidate, which is currently being evaluated in Phase I/ Phase II clinical studies for the treatment of Neoplasms.
Product Name : Undisclosed
Product Type : Antibody-drug Conjugate
Upfront Cash : Inapplicable
September 29, 2025
Lead Product(s) : YL242
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : YL202
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : YL202 is a Antibody-drug Conjugate drug candidate, which is currently being evaluated in Phase I/ Phase II clinical studies for the treatment of Neoplasms.
Product Name : Undisclosed
Product Type : Antibody-drug Conjugate
Upfront Cash : Inapplicable
September 12, 2025
Lead Product(s) : YL202
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

A First-in-Human Study of YL217 in Patients With Advanced Solid Tumors
Details : YL217 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Neoplasms.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
March 05, 2025

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : ZL-6201
Therapeutic Area : Oncology
Study Phase : Preclinical
Recipient : Zai Lab
Deal Size : Undisclosed
Deal Type : Collaboration
Zai Lab Forms Partnership with MediLink for LRRC15 ADC Development
Details : Through the collaboration, Zai Lab further expands its oncology pipeline with another potential first-in-class, ADC ZL-6201 targeting multiple solid tumors.
Product Name : Undisclosed
Product Type : Antibody-drug Conjugate
Upfront Cash : Undisclosed
January 09, 2025
Lead Product(s) : ZL-6201
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Recipient : Zai Lab
Deal Size : Undisclosed
Deal Type : Collaboration

A Phase III Study of YL201 in Recurrent or Metastatic Nasopharyngeal Carcinoma
Details : YL201 is a Other Large Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Nasopharyngeal Carcinoma.
Product Name : Undisclosed
Product Type : Antibody-drug Conjugate
Upfront Cash : Inapplicable
October 08, 2024

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : YL201,Tarlatamab
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Amgen Inc
Deal Size : Undisclosed
Deal Type : Collaboration
MediLink And YL201 Collaborate on Global Clinical Trial And Supply Agreement
Details : Amgen will lead a global clinical study to evaluate the potential of the combination of MediLink's B7-H3-targeting ADC YL201 and Amgen's DLL3- and CD3-targeting BiTE® IMDELLTRA™ in ES-SCLC.
Product Name : Undisclosed
Product Type : Antibody-drug Conjugate
Upfront Cash : Undisclosed
October 07, 2024
Lead Product(s) : YL201,Tarlatamab
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Amgen Inc
Deal Size : Undisclosed
Deal Type : Collaboration

A Phase III Study of YL201 in Relapsed Small Cell Lung Cancer
Details : YL201 is a Other Large Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Small Cell Lung Carcinoma.
Product Name : Undisclosed
Product Type : Antibody-drug Conjugate
Upfront Cash : Inapplicable
September 25, 2024

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : YL205
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Clinical Study of YL205 in Patients With Advanced Solid Tumors
Details : YL205 is a drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Neoplasms.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
June 14, 2024
Lead Product(s) : YL205
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

 Reset All
Reset All